San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug marketplace in February soon after revealing promising data from the mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection and in Mar